Home › Funds › Opaleye Management Inc. › PHAT
Opaleye Management Inc. position in PHAT
Phathom Pharmaceuticals, Inc. · Health Care
Opaleye Management Inc. reported holding 185,589 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q2 2026 13F filing — a position valued at US$2.0M, representing 0.18% of its reported portfolio and ranking #46 among its reported holdings. Opaleye Management Inc. first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s PHAT position evolved
Opaleye Management Inc. first disclosed a stake in PHAT in Q2 2026 at 185,589 shares (US$2.0M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 185.59K | $2.01M | New |
About PHAT and 13F data
PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 31 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $80.99M · Q2 2026
- Carlyle Group Inc. 3.50M sh · $37.94M · Q2 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.05M sh · $11.40M · Q2 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held PHAT?
Opaleye Management Inc. has disclosed PHAT holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Opaleye Management Inc.'s current position in PHAT?
As of Q2 2026, Opaleye Management Inc. holds 185.59K shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $2.01M, representing 0.18% of its reported portfolio and ranking #46.
Has Opaleye Management Inc. been buying or selling PHAT?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. newly opened its position in PHAT.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.